Overview
RIBOLIFE-B (6938)
Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chine...
- Open
- 41.400
- High
- 43.520
- Low
- 37.500
- Prev. Close
- 43.000
- Volume
- 784.36K
- Turnover
- 30.70M
- Avg Price
- 39.136
- Bid/Ask Ratio
- -77.78%
- Amplitude
- 14.00%
- 52wk High
- 95.800
- Volume Ratio
- 1.95
- Turnover Ratio
- 0.46%
- 52wk Low
- 37.500
- HK Mkt Cap
- 6.80B
- Market CapHKD
- 6.80B
- P/ETTM
- Loss
- P/EDynamic
- 145.49
- P/EStatic
- --
- EPSTTM
- -1.15
- EPSDynamic
- 0.276
- EPSStatic
- --
- BVPS
- 11.76
- P/B
- 3.42
- HK Shares
- 169.27M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 169.27M
- Min lot size
- 200
- Currency
- HKD
RIBOLIFE-B Analyst Rating
View moreForecast & Rating
Oct 16, 2026- Strong buy83.33%
- Buy16.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 5
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Suzhou Ribo closed up 3.3% at HK$51.05 after an afternoon rally, reversing an early drop to HK$48.86 for a 7.2% intraday range. The move was driven by the first milestone achievement in the Madrigal collaboration for a MASH siRNA therapy, triggering milestone payments; additionally, the company filed a Phase II clinical trial application with the EMA for its anti-thrombotic siRNA RBD4059 and initiated a Phase III trial in China for the PCSK9 siRNA RBD7022, underscoring pipeline progress. Recent unveiling of the RiboPepSTAR™ platform for extra-hepatic delivery also supported sentiment. However, the stock remains 46.7% below its 52-week high of HK$95.8 and down 37.8% YTD, trading just above the 20-day MA of HK$49.755 but far below the 60-day MA of HK$57.657, with PE at -28.28x and PB at -83.72x reflecting ongoing losses.
News
PUBT · Suzhou Ribo Life Science Files Next-Day Disclosure Return to HKEX Announcing Share Repurchase
Market Movers · Ribolife tumbles 12% in Hong Kong trading
prnewswire · Ribo dépose une demande d'autorisation d'essai clinique européen pour un nouveau siRNA à double ciblage, le SR122, destiné au traitement des dyslipidémies mixtes et sévères, renforçant ainsi sa présence dans le domaine des troubles lipidiques
PUBT · Suzhou Ribo Files EU Application for Phase I Trial of SR122 Lipid Therapy
Market Movers · Ribolife falls 7% in Hong Kong trading
PUBT · Suzhou Ribo Life Science Files Next Day Disclosure Return to HKEX Announcing Share Buyback
